uniQure N.V. (NASDAQ: NASDAQ:QURE), a gene therapy company with a market capitalization of $767 million, announced today the completion of enrollment for the first cohort in a Phase I/IIa trial of AMT-191, an investigational treatment for Fabry disease. Following a safety assessment by the Independent (LON:IOG) Data Monitoring Committee (IDMC), which found no significant safety concerns, the company has been advised to proceed with dosing the second cohort.
Popular
About Us ·
Terms & Condition ·
Contact Us
© Diclofenac News - A dynamic and comprehensive news website 2025. All rights are reserved
© Diclofenac News - A dynamic and comprehensive news website 2025. All rights are reserved